001435053 000__ 03505cam\a2200661\i\4500
001435053 001__ 1435053
001435053 003__ OCoLC
001435053 005__ 20230309003833.0
001435053 006__ m\\\\\o\\d\\\\\\\\
001435053 007__ cr\un\nnnunnun
001435053 008__ 210326s2021\\\\sz\\\\\\ob\\\\000\0\eng\d
001435053 019__ $$a1243542357$$a1253415210
001435053 020__ $$a9783030681807$$q(electronic bk.)
001435053 020__ $$a3030681807$$q(electronic bk.)
001435053 020__ $$a9783030681814$$q(print)
001435053 020__ $$a3030681815
001435053 020__ $$a9783030681821$$q(print)
001435053 020__ $$a3030681823
001435053 020__ $$z9783030681791
001435053 020__ $$z3030681793
001435053 0247_ $$a10.1007/978-3-030-68180-7$$2doi
001435053 035__ $$aSP(OCoLC)1243305466
001435053 040__ $$aYDX$$beng$$erda$$epn$$cYDX$$dGW5XE$$dEBLCP$$dOCLCO$$dOCLCF$$dVT2$$dLIP$$dUKAHL$$dOCLCQ$$dOCLCO$$dCOM$$dOCLCQ
001435053 049__ $$aISEA
001435053 050_4 $$aQP606.P76
001435053 050_4 $$aRM666.E548
001435053 08204 $$a572/.792$$223
001435053 08204 $$a615/.798$$223
001435053 24500 $$aProteinkinase inhibitors /$$cStefan Laufer, editor.
001435053 2463_ $$aProtein kinase inhibitors
001435053 264_1 $$aCham, Switzerland :$$bSpringer,$$c2021.
001435053 300__ $$a1 online resource (vii, 256 pages)
001435053 336__ $$atext$$btxt$$2rdacontent
001435053 337__ $$acomputer$$bc$$2rdamedia
001435053 338__ $$aonline resource$$bcr$$2rdacarrier
001435053 347__ $$atext file
001435053 347__ $$bPDF
001435053 4901_ $$aTopics in medicinal chemistry,$$x1862-2461 ;$$v36
001435053 504__ $$aIncludes bibliographical references.
001435053 5050_ $$aFunction, Structure and Topology of Protein Kinases -- Molecular Modeling of Protein Kinases: Current Status and Challenges -- Covalent Kinase Inhibitors: An Overview -- Achieving High Levels of Selectivity for Kinase Inhibitors -- Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook -- Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR -- Inhibitors of c-Jun N-Terminal Kinase 3 -- Covalent Janus Kinase 3 Inhibitors.
001435053 506__ $$aAccess limited to authorized users.
001435053 520__ $$aThis book reviews the principles of design and examples of successful implementation of proteinkinase inhibitors (PKI), and offers a comprehensive and authoritative overview of the history and latest developments in the field. Chapters written by experts from industry and academia cover the function, structure and topology of Proteinkinases, molecular modelling, disclose how to achieve high level of selectivity for kinase inhibitors, and exploit kinase inhibitors for cancer treatment. Particular attention is given to Inhibitors of c-Jun N-terminal kinase 3, and to covalent Janus Kinase 3 Inhibitors. A case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR is also presented in this book. Given its breath, this book will appeal to medicinal chemists, students, researchers and professionals alike.
001435053 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed April 1, 2021).
001435053 650_0 $$aProtein kinases$$xInhibitors.
001435053 650_0 $$aAntineoplastic agents.
001435053 650_0 $$aPharmaceutical chemistry.
001435053 650_6 $$aAnticancéreux.
001435053 650_6 $$aChimie pharmaceutique.
001435053 655_0 $$aElectronic books.
001435053 7001_ $$aLaufer, Stefan,$$eeditor.
001435053 77608 $$iPrint version:$$z9783030681791$$w(OCoLC)1227381796
001435053 830_0 $$aTopics in medicinal chemistry (Springer (Firm)) ;$$vv. 36.$$x1862-2461
001435053 852__ $$bebk
001435053 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-68180-7$$zOnline Access$$91397441.1
001435053 909CO $$ooai:library.usi.edu:1435053$$pGLOBAL_SET
001435053 980__ $$aBIB
001435053 980__ $$aEBOOK
001435053 982__ $$aEbook
001435053 983__ $$aOnline
001435053 994__ $$a92$$bISE